ArriVent BioPharma, Inc.

AVBP Healthcare Biotechnology

EPS
−16.7%
Free cash flow
−51.5%

Quarter to June 2026, against a year earlier

13.62 1.39 +11.37%
Market cap
$603.0M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
23.63 21.84 13.76 13.14 12.83
Net Debt/EBITDA
0.72 4.43 2.02 2.32 1.73
Debt/Equity
0.00 0.00 0.00 0.00 0.00
ROE
0.00% 55.19% 58.19% (154.10%) (58.88%)
ROA
0.00% (32.68%) (40.08%) (36.75%) (54.70%)
ROIC
(818.42%) (207.99%) (5,134.22%) (151.95%) 0.00%
Return on Tangible Assets
(125.46%) (21.18%) (46.74%) (38.38%) (54.18%)
Free Cash Flow per Share
(17.70) (34.17) (26.08) (2.23) (4.18)
Book value per Share
57.98 136.62 70.67 8.19 7.99
Free Cash Flow
(12.59) (43.63) (55.84) (70.21) (160.59)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026